CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
13vPnCbiological
Likely dose
13vPnC 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03777865
NCT03777865Phase 4Completed
CompareCT.gov

A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA

Pfizer·interventional·Posted Dec 17, 2018·Updated Apr 21, 2020

In Brief

A Phase 4 clinical trial evaluating 13vPnC for Vaccines. Completed, enrolled 100 participants across 4 sites.

Detailed Summary

This is a Phase 4, open-label, single-arm, multicenter study in which subjects 6 to 17 years of age will receive 1 dose of 13vPnC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaccines
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 17, 2018
Enrollment StartDec 14, 2018
Primary CompletionApr 17, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.5 years ago

Interventions

13vPnCbiological

All subjects receive a single dose (0.5mL) of 13vPnC